Accuracy of CA 125 in the diagnosis of ovarian tumors: A quantitative systematic review

Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses

“…So far, cancer antigen 125 (CA125) is the most widely used serum biomarker for detecting and monitoring ovarian cancer in the clinical setting (Bast et al, 2005;Duffy et al, 2005;Sturgeon et al, 2008;Medeiros et al, 2009). Nevertheless, elevated serum CA125 levels are only seen in 50% of patients presented with early stage ovarian cancer and 80%-90% of patients with late stage disease, thus limiting its sensitivity (Molina et al, 1992;Rosen et al, 2005).…”

A Case of Meigs’ Syndrome: The 18F-FDG PET/CT Findings

“…The sensitivity of CA-125 for detecting ovarian malignancy is 80% [9]. However, the CA-125 level is also known to increase in various benign gynecologic conditions.…”

Histological profile and age at diagnosis of breast and ovarian tumors: A register-based study in Espirito Santo, Brazil

“…During the period 2001-2005, the age-adjusted mortality rate due to ovarian cancer was 8.8/100,000 women per year in the United States (6 have been reported. In Germany and the majority of western European countries, ovarian cancer incidence is almost 12/100,000 women, while it is lower in Southern Europe (9.3/100,000 women in Italy) and France (9.7/100,000 women).…”

“…According to data obtained from the Brazilian National Cancer Institute (Instituto Nacional de Câncer, INCA), an incidence ratio of 6.17 cases per 100,000 women is estimated in Brazil for 2012 (6,190 Patients that sought medical assistance at the studied Hospitals are representative of the entire population of Espirito Santo state with regard to breast and ovarian cancer, since the two hospitals are Cancer Reference Hospitals for the residents of the surrounding urban and rural regions.…”